TLSA · Tiziana Life Sciences Ltd

Summary

Tiziana Life Sciences announced positive preclinical data showing nasal anti-CD3 reversed brain aging and improved cognition, reinforcing the mechanism for lead candidate intranasal foralumab.

Key takeaways

• Nasal anti-CD3 dampened microglial activation driving chronic neuroinflammation, potentially mitigating cognitive decline.
• Treatment enhanced neurogenesis in the hippocampus and reduced cellular senescence by downregulating inflammatory markers.
• Findings reinforce the mechanism of action for intranasal foralumab, which stimulates regulatory T cells.
• Clinical programs for intranasal foralumab are ongoing in na-SPMS, MSA, ALS, and Alzheimer's disease.